License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer…
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2…
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and…
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor…
World-renowned researchers with extensive experience in immunology and autoimmune diseases join AltruBio to support scientific advancements and pipeline development Photo…
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
TAICHUNG, Nov. 27, 2024 /PRNewswire/ -- In HIMSS24 APAC Seoul, Healthcare Conference & Exhibition, China Medical University Hospital (CMUH) established…
The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy…
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
GRAND BLANC, Mich., Nov. 25, 2024 /PRNewswire/ -- As healthcare faces increasing demands for precision and efficiency, specialty practices like…